Efficacy comparison of the second generation TKI combined with allogeneic hematopoietic stem cell transplantation or chemotherapy in the treatmeat of Philadelphia chromosome-positive acute lymphoblastic leukemia
10.3760/cma.j.cn421203-20190213-00025
- VernacularTitle:二代TKI联合异基因造血干细胞移植或化学药物治疗Ph ＋ALL的疗效比较
- Author:
Suping ZHANG
1
;
Dingming WAN
;
Zhongxing JIANG
;
Weijie CAO
;
Xue LI
;
Li LI
;
Xinsheng XIE
;
Rong GUO
;
Yanfang LIU
;
Ling SUN
Author Information
1. 郑州大学第一附属医院血液内科 450052
- From:
Chinese Journal of Organ Transplantation
2020;41(6):346-350
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy of the second generation tyrosine kinase inhibitor dasatinib combined with allogeneic hematopoietic stem cell transplantation(allo-HSCT)or chemotherapy in the treatment of Ph + acute lymphoblastic leukemia (Ph + ALL). Methods:A total of 56 Ph + ALL patients received dasatinib from January 2014 to June 2018. According to whether or not allo-HSCT was performed, they were divided into transplantation group(n=22)and chemotherapy group(n=34). The total survival rate(OS), disease-free survival rate(DFS), relapse and non-recurrence mortality(NRM)were compared between two groups. Results:The 2-year OS, DFS and cumulative recurrence rates were 69.1 % vs 47.8 %, 62.2 % vs 43.1 % and 14.6 % vs 44.1 % in transplantation and chemotherapy groups respectively. Significant inter-group differences existed in 2-year DFS, DFS and cumulative recurrence rates. The value of NRM was higher in transplantation group than that in chemotherapy group(18.6 % vs 14.1 %). However, the difference was statistically insignificant( P=0.476). Conclusions:The efficacy of dasatinib plus allo-HSCT is superior to that of dasatinib plus chemotherapy in the treatment of Ph + ALL.
